People /

Jean-Patrice Labautière

Partner

Paris

People /

Jean-Patrice Labautière

Partner

Paris

Jean-Patrice Labautière

Partner

Paris

T: +33 (0) 1 44 17 77 36

Français

Biography

Jean-Patrice Labautière conseille des entreprises françaises et étrangères, des institutions financières et des investisseurs privés dans le cadre de fusions-acquisitions et d'opérations de capital-investissement. Il possède une expérience significative dans la structuration, la négociation et la documentation d'acquisitions complexes, de rachats d'entreprises par effet de levier, de réorganisations d'entreprises et de joint-ventures impliquant la coordination d'équipes juridiques de différentes juridictions.

Jean-Patrice conseille sur tous les types de transactions d'entreprise d'une manière pratique et orientée business.

Areas of Focus

Health & Safety
Technology Transactions
Financial Institutions
Financial Services

Civic Involvement & Honors

Ranked in the "Best Lawyers in France 2024"
Nominated by clients “Lawyer of the Year” in Private Equity (Palmarès du Droit 2022).
Ranked as a “Star” by Acritas and in The Legal 500, and various French legal directories in M&A, Private Equity and for Healthcare transactions.

Admissions

Paris
England & Wales (Registered Foreign Lawyer)

Related Capabilities

M&A & Corporate Finance
Healthcare & Life Sciences
Corporate
Financial Institutions

Experience

Represented Vantiva SA (ex-Technicolor SA) with the sale of its Supply Chain Solutions business to funds managed by Variant Equity Advisors.
Represented Société BIC in relation to the acquisition of Tangle Teezer from Mayfair Equity Partners.
Represented Vantiva SA (ex-Technicolor SA) in relation to the acquisition of the Home Networks division of CommScope (Nasdaq: COMM) in consideration for 25% of the share capital of Vantiva SA.
Represented Technicolor SA in connection with the sale of its Trademark Licensing operations to one of the largest diversified financial institutions for approx. €100 million in cash.
Represented Eurazeo Healthcare in relation to its investment in Groupe Novair.
Represented Ipsos in relation to a number of matters, including:
- the acquisition of GfK’s Custom Research Business in 25 countries;
- the creation of Ipsos Partners, a management company with approx. 150 managers of the Ipsos group in the World;
- the acquisition of Synovate from Aegis;
- the acquisition of OTX; and
- the acquisition of MORI.
Represented bioMérieux in relation to acquisitions and a tripartite joint venture.
Advised Laboratoires Pierre Fabre in relation to the disposal of Glytone.
Represented Riverside Europe Partners on number of matters, including:
- working with them and the founders of HRA Pharma in relation to the sale of HRA Pharma to Astorg Partners and Goldman Sachs;
- the acquisition of Soft Medical Europe;
- the sale of Orliman to Magnum Capital; and
- in relation to its investment in HRA Pharma.
Represented Sanofi Pasteur-MSD in relation to the termination of the joint vaccine activities of Sanofi and Merck in Europe.
Represented Double A in relation to the sale of DA Alizay to VPK.
Represented Leading Debt Funds and a Leading Servicer in relation to the acquisition of several NPL Portfolios.
Represented ABN AMRO in relation to the disposal of its direct assets management business to Candriam.